Nitin V Kolhe, Mohamed T Eldehni, Nicholas M Selby, Christopher W McIntyre
{"title":"急性肾损伤的报销和费用:英国医院的观点。","authors":"Nitin V Kolhe, Mohamed T Eldehni, Nicholas M Selby, Christopher W McIntyre","doi":"10.1159/000358435","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite the great interest in acute kidney injury (AKI), there have been very few studies that examined the economic impact and costing methodologies of AKI. We aimed to examine the cost and income of AKI in hospitalised patients over a period of 1 year using the NHS costing system related to that year.</p><p><strong>Methods: </strong>A total of 627 patients discharged between January 2008 and December 2008 with AKI were identified by International Classification of Disease 10 codes (ICD-10). Basic demographic data were collected using the hospital electronic records, and the severity of AKI was classified according to the Acute Kidney Injury Network (AKIN) classification. We calculated the total income and isolated the AKI income related to AKI-specific finished consultant episodes. Then we conducted a patient level costing exercise using relative value units (RVU) to compare the cost of AKI to the actual income.</p><p><strong>Results: </strong>The total spell income for all patients was GBP 1,954,922.7; the mean total income per patient was GBP 3,752.3 (95% CI 3,594.6-3,903.9). AKIN stage 3 generated significantly higher total spell and AKI income. The estimated overall cost of treating AKI was higher than the AKI income to the Primary Care Trust (GBP 1,984,543.9 vs. 1,755,395).</p><p><strong>Conclusion: </strong>AKIN stage 3 has a significant economic impact when compared with AKIN stages 1 and 2. The move towards a patient level costing using RVU could be a more efficient way to match cost and income.</p>","PeriodicalId":19094,"journal":{"name":"Nephron Clinical Practice","volume":"126 1","pages":"51-6"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000358435","citationCount":"18","resultStr":"{\"title\":\"The reimbursement and cost of acute kidney injury: a UK hospital perspective.\",\"authors\":\"Nitin V Kolhe, Mohamed T Eldehni, Nicholas M Selby, Christopher W McIntyre\",\"doi\":\"10.1159/000358435\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Despite the great interest in acute kidney injury (AKI), there have been very few studies that examined the economic impact and costing methodologies of AKI. We aimed to examine the cost and income of AKI in hospitalised patients over a period of 1 year using the NHS costing system related to that year.</p><p><strong>Methods: </strong>A total of 627 patients discharged between January 2008 and December 2008 with AKI were identified by International Classification of Disease 10 codes (ICD-10). Basic demographic data were collected using the hospital electronic records, and the severity of AKI was classified according to the Acute Kidney Injury Network (AKIN) classification. We calculated the total income and isolated the AKI income related to AKI-specific finished consultant episodes. Then we conducted a patient level costing exercise using relative value units (RVU) to compare the cost of AKI to the actual income.</p><p><strong>Results: </strong>The total spell income for all patients was GBP 1,954,922.7; the mean total income per patient was GBP 3,752.3 (95% CI 3,594.6-3,903.9). AKIN stage 3 generated significantly higher total spell and AKI income. The estimated overall cost of treating AKI was higher than the AKI income to the Primary Care Trust (GBP 1,984,543.9 vs. 1,755,395).</p><p><strong>Conclusion: </strong>AKIN stage 3 has a significant economic impact when compared with AKIN stages 1 and 2. The move towards a patient level costing using RVU could be a more efficient way to match cost and income.</p>\",\"PeriodicalId\":19094,\"journal\":{\"name\":\"Nephron Clinical Practice\",\"volume\":\"126 1\",\"pages\":\"51-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000358435\",\"citationCount\":\"18\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nephron Clinical Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000358435\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2014/2/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephron Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000358435","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/2/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 18
摘要
背景:尽管人们对急性肾损伤(AKI)有很大的兴趣,但很少有研究检查AKI的经济影响和成本计算方法。我们的目的是使用与该年相关的NHS成本系统检查住院患者在1年期间的AKI成本和收入。方法:采用国际疾病分类第10号代码(ICD-10)对2008年1月至2008年12月出院的627例AKI患者进行鉴定。使用医院电子病历收集基本人口统计数据,并根据急性肾损伤网络(AKIN)分级对AKI的严重程度进行分级。我们计算了总收入,并分离了与AKI相关的AKI收入。然后,我们使用相对价值单位(RVU)进行了患者水平的成本计算,以比较AKI的成本与实际收入。结果:所有患者的法术总收入为1,954,922.7英镑;每位患者的平均总收入为3,752.3英镑(95% CI 3,594.6-3,903.9)。AKIN阶段3产生了显著更高的法术和AKI总收入。治疗AKI的估计总成本高于初级保健信托的AKI收入(1,984,543.9英镑对1,755,395英镑)。结论:与AKIN 1期和2期相比,AKIN 3期具有显著的经济影响。使用RVU向患者水平成本的转变可能是匹配成本和收入的更有效方法。
The reimbursement and cost of acute kidney injury: a UK hospital perspective.
Background: Despite the great interest in acute kidney injury (AKI), there have been very few studies that examined the economic impact and costing methodologies of AKI. We aimed to examine the cost and income of AKI in hospitalised patients over a period of 1 year using the NHS costing system related to that year.
Methods: A total of 627 patients discharged between January 2008 and December 2008 with AKI were identified by International Classification of Disease 10 codes (ICD-10). Basic demographic data were collected using the hospital electronic records, and the severity of AKI was classified according to the Acute Kidney Injury Network (AKIN) classification. We calculated the total income and isolated the AKI income related to AKI-specific finished consultant episodes. Then we conducted a patient level costing exercise using relative value units (RVU) to compare the cost of AKI to the actual income.
Results: The total spell income for all patients was GBP 1,954,922.7; the mean total income per patient was GBP 3,752.3 (95% CI 3,594.6-3,903.9). AKIN stage 3 generated significantly higher total spell and AKI income. The estimated overall cost of treating AKI was higher than the AKI income to the Primary Care Trust (GBP 1,984,543.9 vs. 1,755,395).
Conclusion: AKIN stage 3 has a significant economic impact when compared with AKIN stages 1 and 2. The move towards a patient level costing using RVU could be a more efficient way to match cost and income.